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Model-based identiﬁcation of TNFα-induced IKKβ-mediated
and IκBα-mediated regulation of NFκB signal transduction as
a tool to quantify the impact of drug-induced liver injury
compounds
Angela Oppelt1, Daniel Kaschek2, Suzanna Huppelschoten3, Rowena Sison-Young4, Fang Zhang4, Marie Buck-Wiese1,
Franziska Herrmann1, Sebastian Malkusch5, Carmen L. Krüger5, Mara Meub5, Benjamin Merkt2, Lea Zimmermann1, Amy Schoﬁeld4,
Robert P. Jones4,6, Hassan Malik6, Marcel Schilling 1, Mike Heilemann5,7, Bob van de Water3, Christopher E. Goldring4, B. Kevin Park4,
Jens Timmer2,8 and Ursula Klingmüller 1
Drug-induced liver injury (DILI) has become a major problem for patients and for clinicians, academics and the pharmaceutical
industry. To date, existing hepatotoxicity test systems are only poorly predictive and the underlying mechanisms are still unclear.
One of the factors known to amplify hepatotoxicity is the tumor necrosis factor alpha (TNFα), especially due to its synergy with
commonly used drugs such as diclofenac. However, the exact mechanism of how diclofenac in combination with TNFα induces liver
injury remains elusive. Here, we combined time-resolved immunoblotting and live-cell imaging data of HepG2 cells and primary
human hepatocytes (PHH) with dynamic pathway modeling using ordinary differential equations (ODEs) to describe the complex
structure of TNFα-induced NFκB signal transduction and integrated the perturbations of the pathway caused by diclofenac. The
resulting mathematical model was used to systematically identify parameters affected by diclofenac. These analyses showed that
more than one regulatory module of TNFα-induced NFκB signal transduction is affected by diclofenac, suggesting that
hepatotoxicity is the integrated consequence of multiple changes in hepatocytes and that multiple factors deﬁne toxicity
thresholds. Applying our mathematical modeling approach to other DILI-causing compounds representing different putative DILI
mechanism classes enabled us to quantify their impact on pathway activation, highlighting the potential of the dynamic pathway
model as a quantitative tool for the analysis of DILI compounds.
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INTRODUCTION
Drug-induced liver injury (DILI) is currently one of the most
important obstacles during drug development. To date, over 1000
drugs are known to cause DILI,1 affecting not only a restricted
group of patients, but a broad range of medications and
treatments.2 Current test systems employed by the pharmaceu-
tical industry are poorly predictive since the underlying mechan-
isms are still unclear. So far, the majority of studies focused on the
effects of compounds on hepatocytes, whereas the impacts of
synergistic drug–cytokine interactions were rarely considered.
Furthermore, due to the complexity of the impact of compounds
on the dynamic behavior of the intracellular signaling network,
the impacts of multiple factors have to be considered.
One of the top ten DILI-causing compounds is diclofenac (DCF),
a commonly used nonsteroidal anti-inﬂammatory drug. DCF was
shown to synergize with tumor necrosis factor alpha (TNFα) by
accelerating apoptosis in primary human hepatocytes (PHH) and
HepG2 cells3,4 by enhancing endoplasmic reticulum stress as well
as oxidative stress.5 However, the exact underlying mode of action
remained to be elucidated. TNFα signal transduction, apart from
being a key mediator of inﬂammatory responses, plays also a
major role in apoptosis. It was observed that there is a tightly
regulated and very complex balance between TNFα-induced pro-
survival signaling via complex I and death signaling via complex
II.6,7 The TNFR1-Membrane-Associated Proximal Complex (com-
plex I) is rapidly formed at the plasma membrane and is
composed of the receptor itself, TRADD, RIP, TRAF2, and cIAP1,
but is devoid of caspase 8 and triggers only the NFκB response but
no apoptotic signaling.6 TNFα was reported to enhance cell
death8,9 if the NFκB-induced inhibition of apoptotic signaling via
JNK or necroptotic signaling via RIP fails.10 Because NFκB signal
transduction is extremely complex due to a multitude of feedback
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regulators, it has been previously examined by applying
mathematical modeling that is a powerful tool to study multi-
factorial and complex networks.11–15 Since it was proposed that
the IκB kinase (IKK) signaling module is highly relevant for the
temporal control of NFκB signal transduction,16 several mathe-
matical models included the IKK module.11,15,17,18 However, a
potential role of IKK in drug-induced hepatotoxicity upon
inﬂammatory responses so far has not been addressed. IKK is a
multi-protein complex composed of IKKα, IKKβ, and the regulatory
IKKγ (NEMO) that phosphorylates IκB and thereby facilitates
degradation of IκB inhibitors and the subsequent translocation of
NFκB to the nucleus.19,20 The activity of the IKK is controlled by
positive and negative regulatory phosphorylation cycles modu-
lated by a network of components of the TNF receptor (TNFR)
complex.19,20 Speciﬁcally, activation by TNFα binding to the
receptor leads to the phosphorylation of two sites in the activation
loop of IKKβ, which is essential for the activation of the NFκB
pathway. During this highly active state, IKKβ undergoes extensive
autophosphorylation at multiple sites at the C-terminus,21 which
leads to a massive downregulation of its activity. If both the
activation loop and the C-terminus are phosphorylated, IKKβ is still
active, although with almost no catalytic activity. Rather, this state
facilitates the recruitment of phosphatases deactivating IKK by
dephosphorylation of its activation loop. This in turn creates an
inactive state that is refractory to activation by TNFα.22 Therefore,
another dephosphorylation event has to take place resulting in
the non-phosphorylated state of IKKβ that is free to be re-
activated by the receptor complex. In sum, the activity of IKK and
thereby the activation of NFκB signal transduction is tightly
regulated at the level of IKK by a four-step phosphorylation/
dephosphorylation process.22 The latent transcription factor NFκB
is regulated by the inhibitor of NFκB, IκBα, which sequesters NFκB
in the cytoplasm. IκBα in complex with NFκB is a substrate for the
IKK complex.23,24 Phosphorylation of IκBα prompts it for ubiqui-
tination leading eventually to the degradation of IκBα and the
release and nuclear translocation of NFκB. These steps provide
another important regulatory mechanism to control the activation
of NFκB signal transduction downstream of the TNFR complex.
To examine mechanisms responsible for the impact of DCF on
TNFα-induced hepatotoxicity, we considered the highly inter-
twined signaling components and applied a data-based mathe-
matical modeling approach. While the NFκB pathway has been
extensively studied in the past and several dynamic pathway
models exist, these mathematical models did not address the
effect of DCF on the TNFα-induced NFκB signal transduction
pathway. In the presented study, we generated quantitative data
in the human hepatocellular carcinoma cell line HepG2 and in
PHHs under standardized conditions. Jointly estimating para-
meters of our dynamic pathway model from the standardized data
enabled us to attribute the observed alterations in the dynamics
of TNFα-induced NFκB signal transduction in response to co-
treatment with DCF to speciﬁc changes in parameters of the
reaction network. To this end, previously established methods of
model selection and L1 regularization
25,26 were employed to
determine the most likely interaction points between DCF and
TNFα-induced NFκB signal transduction. The systematic analyses
of the calibrated model revealed the interplay of IKK-mediated
and IκBα-mediated regulation of the dynamics of NFκB in the
nucleus and thereby explained the DCF-induced alterations of
NFκB oscillations in nucleus and cytoplasm. With a mathematical
model generalized to explain drug-induced IKK and IκBα
regulation it was possible to quantify the impact of four additional
DILI compounds (amiodarone, paracetamol, ximelagatran, and
ﬁaluridine) on TNFα-induced NFκB activation.
RESULTS
Dynamic pathway model of TNFα-induced NFκB signal
transduction
To develop a mathematical model for TNFα-induced NFκB signal
transduction (Fig. 1a), we generated time-resolved data of several
pathway components of the canonical NFκB pathway in the
human hepatocellular carcinoma cell line HepG2 and in PHHs.
Since it was previously reported that DCF affects the oscillatory
behavior of NFκB, we ﬁrst examined the dynamics of TNFα-
induced nuclear translocation of NFκB and the corresponding
production of the target gene A20. We utilized HepG2 cells stably
expressing GFP-tagged RelA, a subunit of NFκB (further referred to
as NFκB-GFP HepG2) and monitored by life cell imaging the
localization of NFκB in the cytoplasm and the nucleus upon
stimulation with TNFα. The NFĸB-GFP intensity was simultaneously
quantiﬁed in several hundred cells, yielding an average dynamics
(Fig. 1b, data points in upper two panels). As shown in Fig. S1, the
single-cell dynamics of NFĸB nuclear translocation was highly
consistent with the average dynamics, corroborating our
approach to analyze the average data and use it for mathematical
modeling. Further, we quantiﬁed the time course of A20
expression in response to TNFα stimulation in HepG2 cells stably
expressing GFP-tagged A20 (A20-GFP HepG2) (Fig. 1b, data points
in lower panel). These examinations showed that TNFα-induced
nuclear accumulation of NFĸB reaches its ﬁrst peak after 25 min
followed by a second peak at 122 min. The timing of maximal
accumulation of NFĸB in the nucleus mirrored the maximal
reduction of NFĸB from the cytoplasm showing the expected
complementary dynamics. The expression of the target gene A20
was initiated as soon as 50 min past TNFα stimulation, which is
shortly after the ﬁrst peak of nuclear NFĸB, and kept increasing for
the entire observation time of 6 h.
To simultaneously examine the dynamics of pathway activation
of multiple key components of the canonical NFκB signal
transduction pathway, we used quantitative immunoblotting
and determined the dynamics of IKK, IκBα, and NFκB phosphor-
ylation and of IκBα abundance in HepG2 cells that were either
stimulated with TNFα or were left untreated. Comparable
experiments were performed with PHH that were treated with
TNFα. As depicted in Fig. 1c for HepG2 cells and in Fig. 1d for PHH,
in both cell types the key components of the canonical NFκB
signal transduction pathway were phosphorylated after 10–20min
of TNFα stimulation. Likewise, the overall dynamics of pathway
activation was very comparable in HepG2 cells and PHH,
corroborating the use of the HepG2 cell line as model system.
However, the extent of IκBα and NFĸB phosphorylation was
slightly lower in PHH compared to HepG2 cells. Further, shortly
after the ﬁrst peak of the IKK, IκBα, and NFκB phosphorylation the
cytoplasmic levels of IκBα reached the lowest values after TNFα
stimulation at 20 min in both HepG2 cells and PHH. Finally, to
quantify the dynamics of phosphorylation events of the NFĸB:IκBα
complex, we performed co-immunoprecipitation experiments (Co-
IP) in HepG2 cells that were stimulated with TNFα. Cellular lysates
taken at different time points of TNFα stimulation were subjected
to immunoprecipitation with antibodies recognizing IĸBα or NFĸB.
In immunoblotting experiments we examined the time course of
immunoprecipitated IκBα in the cytoplasm as well as the complex
formation with NFκB and phosphorylated NFκB. For immunopre-
cipitated NFκB the dynamics of NFκB phosphorylation was
monitored as well as the complex formation with IĸBα and
phosphorylated IĸBα (Fig. 1e). The obtained results showed that
the peak of NFκB:pIĸBα complex and of pNFκB:IĸBα slightly
preceded the maximum of TNFα-induced NFκB phosphorylation.
Based on these comprehensive time-resolved examinations an
ordinary differential equation (ODE)-based dynamic pathway
model of TNFα-induced NFκB signaling (Fig. 1a) was developed.
First, a model with a multitude of independent reaction rates
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involving IKK, NFĸB, and IĸBα phosphorylation as well as complex
formation was established (Fig. S2). Based on this comprehensive
model, the major processes contributing to the signaling pathway
were identiﬁed by inspecting all reaction ﬂuxes (Fig. S3). To
describe the upstream processes leading to the activation of the
NFκB pathway, we included four IKK states in the dynamic
pathway model that are denoted as IKK, phosphorylated (p) IKK,
multiply phosphorylated (pp) IKK, and inactive (i) IKK. These states
Fig. 1 TNFα-induced NFκB signaling pathway model for HepG2 cells and primary human hepatocytes (PHH). a Schematic representation of
the model according to Systems Biology Graphical Notation indicating the considered components and reactions. Arrows indicate
biochemical reactions. Boxes with round corners symbolize proteins, parallelograms represent RNA. Slashed circles represent degradation or
production. Experimental data was acquired by either live-cell ﬂuorescence microscopy (b) of NFκB translocation (cytoplasm and nuclei, n= 3)
and of A20 expression dynamics (n= 1) in HepG2 cells stably expressing NFκB-GFP or A20-GFP, respectively, or quantitative immunoblotting
(c–e) of cytoplasmic lysates of HepG2 cells (c, n= 3–6, raw data in Figs. S8–S17) and PHHs (d, n= 3 donors, raw data in Figs. S18–S21) or
immunoprecipitations (e, n= 1–3, raw data in Figs. S22–S29) treated with TNFα (10 ng/ml). Data points with 1σ conﬁdence intervals computed
from replicates are indicated by dots with error bars, lines indicate trajectories of the calibrated model
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Fig. 2 Identiﬁcation of diclofenac effects. a Increasing regularization strength λ forces parameter differences between the mathematical
model describing TNFα-stimulated control data and the model with modiﬁed rates based on the data of TNFα and DCF-treated cells to vanish.
The eleven parameters disappearing last are indicated as colored paths, early disappearing effects are shown in gray. b Every vanishing effect
reduces the model complexity by one, shown in blue. Accordingly, the ﬁt quality decreases indicated by larger contributions from the data
points to the objective value, indicated in black. The regularization value, shaded area, reaches its maximum when regularization strength and
model complexity balance out. Regularization and data contribution sum up to the total objective value, shown as red line. c The core model
with a total of seven diclofenac-speciﬁc rate parameters was ﬁtted to the experimental data. Data points with 1σ conﬁdence intervals
computed from replicates are indicated by dots with error bars, model ﬁts are shown as solid lines. Experimental data was acquired by either
live-cell ﬂuorescence microscopy of NFκB translocation (cytoplasm and nuclei, n= 3) and of A20 expression dynamics (n= 1) in HepG2 cells
stably expressing NFκB-GFP or A20-GFP, respectively, or by quantitative immunoblotting of cytoplasmic lysates (n= 3–6, raw data in Figs. S8–
S17) or immunoprecipitations (n= 1–3, raw data in Figs. S22–S29) of HepG2 cells, either untreated, treated with TNFα alone (10 ng/ml), treated
with diclofenac (500 µM) alone or co-treated with TNFα (10 ng/ml) and diclofenac (500 µM)
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are based on sequential events induced by TNFα: ﬁrst, the kinase
domain is phosphorylated at the activation loop leading to full
kinase activity (pIKK). Second, the C-terminal serines are phos-
phorylated, while the kinase domain is still phosphorylated
(ppIKK). In the ppIKK state, IKKβ has very low catalytic activity.
Finally, IKKβ is inactivated (iIKK) due to dephosphorylation of the
activation loop and needs a recovery time before it can be
activated again (IKK). Because the antibody applied for measuring
the phosphorylation of IKK is detecting the phosphorylation in the
activation loop, the immunoblotting measurements represent
both pIKK and ppIKK. However, according to our ﬂux analysis, only
pIKK has an impact on IĸBα and NFĸB phosphorylation within the
complex. Because phosphorylation of IĸBα triggers the dissocia-
tion of the NFκB:IκBα complex, this results in our model in free
NFĸB, either phosphorylated or not. The reaction ﬂuxes showed
that both states are necessary and fulﬁll a different purpose.
Inspecting the gain terms of the NFĸB:IĸBα complex we found that
complex formation in the cytoplasm of unphosphorylated NFĸB
with de novo produced IĸBα is almost as strong as the supply by
complexes exported from the nucleus. Another ﬁnding from the
analysis of the reaction ﬂuxes was that the newly synthesized A20
protein, although being known to be a negative feedback on
TNFα-mediated IKK activation, has a negligible inhibitory impact
on IKK. Based on the analysis of the reaction ﬂuxes a much
reduced mathematical model was developed. Further reduction
steps were introduced based on the proﬁle likelihood method.
The proﬁle likelihood analysis pointed out that several estimated
parameters, e.g., nuclear NFĸB dephosphorylation, complex
formation and export, are likely to operate on a faster timescale
than other reactions, and therefore cannot be constrained by
upper conﬁdence bounds based on the data. Finally, the
combination of ﬂux and proﬁle likelihood analysis led to a fully
identiﬁable core model capable of describing the dynamics of
TNFα-induced activation of NFĸB signal transduction in HepG2
cells (Fig. 1b, c, e). A list of all reaction equations and parameter
values is provided in Supplementary Material 1 (Tables S5–S7).
Identiﬁcation of DCF targets in the TNFα-induced NFκB signal
transduction pathway
To assess the impact of DCF on the TNFα-induced NFκB signal
transduction pathway, we quantiﬁed the dynamics of the
respective components in HepG2 cells in the presence or absence
of DCF using quantitative immunoblotting and live-cell imaging
(Fig. 2c, symbols). To select a suitable DCF dose, the impact of
increasing doses of DCF on TNFα-induced IκB phosphorylation
was examined (Fig. S7). In these experiments a major reduction of
TNFα-induced IκB phosphorylation was observed upon treatment
with 500 μM DCF. Since in a previous publication a substantial
enhancement of DCF toxicity was observed upon treatment with
500 μM DCF and TNFα,5 this DCF concentration was selected for all
measurements. DCF was added to the cells 30 min prior to
stimulation with TNFα. The most prominent effects of co-
treatment of TNFα and DCF were a delay of the second NFĸB
peak in the nucleus and a reduced A20 production. Speciﬁcally, in
the presence of TNFα and DCF the ﬁrst peak of nuclear NFĸB was
delayed by 8min and slightly exceeded the maximum level
observed for TNFα treatment alone. The phase of low NFĸB levels
was prolonged in TNFα and DCF co-treated HepG2 cells relative to
TNFα treatment alone and the second peak of nuclear NFĸB was
delayed by 56min. Also the levels of nuclear NFĸB were lower for
TNFα and DCF co-treated cells. These effects were preceded by
delayed and reduced concentrations of IĸBα, phosphorylated IĸBα,
and NFĸB in the cytoplasm after 30 min of co-stimulation.
To systematically identify putative targets of DCF in the TNFα
signaling network, we utilized the established core model of TNFα-
induced NFκB signal transduction to analyze the time-resolved
live-cell imaging and immunoblotting data of the TNFα-stimulated
HepG2 cells that were either co-treated with DCF or not (Fig. 2c,
data points). For simultaneous parameter estimation in TNFα and
DCF co-treated or untreated cells, L1 regularization was used to
gradually reduce the number of hypothesized interactions
between DCF and the reaction network. For different values of
the regularization strength λ, the regularized objective function
lλ(k, Δk) was optimized with respect to the original parameters k
and the DCF-speciﬁc parameters Δk. In Fig. 2a, the estimated Δ-
values are shown as function of the regularization strength λ. With
increasing λ, more and more parameters were reduced to the
baseline indicating that their effect is estimated to be negligible.
The 11 parameters that were reduced last to the baseline are
indicated by colored lines. These parameters are retained, since
they are most essential to maintain a good ﬁt between data and
model when the number of non-zero difference parameters is
reduced. The decline of non-zero parameters is shown as a blue
line in Fig. 2b. For comparison, the objective value with and
without the regularization contribution are shown in red and
black, respectively. The shaded area, i.e., the regularization
contribution, indicates that for high enough regularization
strength the number of non-zero Δ-parameters is decreased to
an extent that the regularization contribution vanishes. However,
at this point the ﬁt between data and model deteriorated by 400
in terms of twice the negative log-likelihood compared to the
model with 24 Δ-parameters. According to a likelihood ratio test,
deterioration of the likelihood becomes highly signiﬁcant (p <
0.001) when the penalty strength passes the threshold of λ= 10,
corresponding to 11 non-zero effects and a difference of 34 in
terms of twice the negative log-likelihood.
The list of non-zero effects revealed that the major targets of
DCF are IKK activation and IĸBα production and degradation. In
addition, the production of A20 appeared to be directly affected.
Of note is that some of the curves depicted in Fig. 2a were
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Fig. 3 Primary human hepatocytes data and ﬁt. Experimental data
was acquired by quantitative immunoblotting of cytoplasmic lysates
of primary human hepatocytes treated with either TNFα alone
(10 ng/ml) or with TNFα (10 ng/ml) and diclofenac (500 µM). Data
points with 1σ conﬁdence intervals computed from independent
donors (n= 3, raw data in Figs. S18–S21) are indicated by triangles
and error bars. Only the model parameters speciﬁc for DCF
treatment, observation-speciﬁc scaling and offset parameters and
a global time-scale parameter were adjusted to predict the correct
IKK, IκBα, and NFκB proﬁles
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overlapping. For example, IKK activation by the TNFR1 (light blue)
and TNFR1 activation (brown) cannot be distinguished in the plot.
A change of either rate parameter had the same effect on the
model response and therefore these parameters were considered
as not independent. Based on the obtained results, seven DCF-
speciﬁc reaction rates were identiﬁed to be independent: the
activation of IKK by TNFα, the recovery of iIKK, the
phosphorylation of pIKK, the phosphorylation of IĸBα by pIKK,
the production and degradation of IĸBα mRNA, and, ﬁnally, the
translation of A20 mRNA were introduced into the model yielding
the TNFα signaling DCF model. As a result, the data from HepG2
cells treated either with TNFα alone or in with a combination of
TNFα and DCF were successfully described by the same model
topology (Fig. 2c, solid lines).
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Fig. 4 Impact of DCF on TNFα and TNFR1 interaction. a Concentration time courses of pIKK, non-phosphorylated NFκB–IκBα complex in the
cytoplasm and free, non-phosphorylated NFκB in the nucleus were simulated for TNFα concentrations between 0.1 and 1000 ng/ml. In the
experiment 10 ng/ml were applied. The ﬁrst maximum of pIKK and the ﬁrst two maxima of nuclear NFĸB are indicated by dots. The different
TNFα levels have a large effect on the peak height and position of pIKK relative to NFκB–IκBα complex and nuclear NFκB that remain almost
unchanged for higher TNFα concentrations and exhibit a minorly reduced and delayed response for lower TNFα concentrations. b–e dSTORM
imaging of TNFR1 in the plasma membrane of HepG2 cells. b Respresentative dSTORM image of TNFR1 labeled via indirect
immunocytochemistry on the plasma membrane of HepG2 cells (inset: brightﬁeld image) (scale bar 5 µm). c Magniﬁcation of the inset
indicated in b (scale bar 500 nm). d Number of TNFR1 clusters on the cell membrane at the indicated time points before and after induction
with TNFα (gray: non-stimulated cells, black: TNFα-stimulated cells, blue: negative control with secondary antibody only). e Number of TNFR1
clusters for cells pre-treated with DCF (light red) followed by induction with TNFα (red) (number of cells measured under each condition n ≥
13). Stimulation with TNFα shows no signiﬁcant change to the according unstimulated population. Pre-treatment with DCF shows no
signiﬁcant changes in regard to untreated cells. Box plots in d and e indicate the median (line in box), lower and upper quartile (box), the
mean value (square), and the data range (asterisks). Whiskers represent 1.5× the interquartile distance. Statistical analysis was performed using
the Kolmogorov–Smirnov test with signiﬁcance level α= 0.05
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Impact of DCF on TNFα-induced NFκB signal transduction in PHHs
To verify that the model-identiﬁed impact of DCF on TNFα-
induced NFκB signal transduction holds true in primary liver cells,
we tested the TNFα signaling DCF model on data from freshly
isolated PHHs, stimulated with TNFα in the presence or absence of
DCF (Fig. 3). Since the availability of PHH is very limited, we
focused our analysis on immunoblotting experiments and
selected time points that were most informative in the analysis
of the DCF effects on TNFα-induced NFκB signal transduction in
HepG2 cells. As demonstrated in Fig. 1, the overall dynamics of
pathway activation in PHH was highly consistent with the pathway
activation dynamics observed in HepG2 cells, but appeared to be
slower than in HepG2 cells. To consider this difference in timing,
we introduced a global time-scale parameter affecting all reaction
rates in the mathematical model. To account for the difference in
signal strength and background in the immunoblotting experi-
ments performed with PHH, observation parameters such as signal
scale and offset were independently estimated. Furthermore,
although we assume that the mechanism by which DCF acts on
TNFα signaling in PHH is very comparable to HepG2 cells, the
strength of DCF may vary in the primary cells. Taken together, a
time-scale parameter, scaling and offset parameters, as well as the
DCF-speciﬁc parameters were estimated from the PHH data,
whereas all other parameter, i.e., reaction rates of the NFκB
signaling network were unchanged. The resulting model trajec-
tories shown in Fig. 3 are in agreement with the experimental
data, conﬁrming that our mathematical model can also be applied
to data generated in primary cells. Furthermore, experimental data
and mathematical model simulation demonstrated that also in
PHH DCF has a strong and early impact on TNFα-induced NFκB
signal transduction. In cells co-treated with TNFα and DCF, the
activation of IKK was more transient and recovery of IκBα,
phosphorylated IκBα, and phosphorylated NFκB were much
reduced compared to TNFα-treated cells. These observations
underpin the broad applicability of the developed model to
quantitatively assess the impact of DCF on TNFα-induced NFκB
signal transduction.
Impact of DCF on the TNFα/TNFR1 interaction in HepG2 cells
The L1 regularization approach identiﬁed seven reaction rates in
the signaling network as possible targets of DCF, including IKK
activation. In principle, the predicted reduced IKK activation in
TNFα and DCF co-treated cells could be mediated by a direct
interference of DCF with TNFα binding to its receptor resulting in
reduced TNFα levels available for the initiation of signal
transduction. To explore this mechanism and evaluate if reduced
TNFα levels alone could explain the observed effects of DCF on
TNFα-induced NFĸB signal transduction, we utilized our TNFα
signaling DCF model and simulated the dynamics of key
components of the signaling pathway, pIKK, NFĸB:IĸBα complex,
and nuclear NFĸB in response to different TNFα concentrations.
We used the experimentally applied 10 ng/ml TNFα as reference
and predicting with the model the dynamics for higher (100 and
1000 ng/ml) and lower (1 and 0.1 ng/ml) TNFα doses (Fig. 4a). The
model trajectories showed that increasing TNFα concentrations
above the experimentally applied 10 ng/ml of TNFα resulted in an
increase of IKK phosphorylation levels but not in an increase in the
peak height of nuclear NFĸB. This effect can be understood from
the predicted dynamics of the NFĸB:IĸBα complex concentration.
Already the reference TNFα concentration of 10 ng/ml lead to the
dissociation of almost all NFĸB:IĸBα complexes. Even for TNFα
concentrations as low as 0.1 ng/ml, more than 90% of all NFĸB:
IĸBα complexes dissociated. Accordingly, the peak height of
nuclear NFĸB showed only a small variation between different
TNFα concentrations. Interestingly, the model simulations
revealed only a minor difference in the time of the ﬁrst and the
second peak of nuclear NFĸB upon lowering the TNFα
concentration (dots in Fig. 4a). These predictions were in contrast
to the observed impact of DCF (Fig. 2c) characterized by
prolonged low levels of NFĸB in the nucleus followed by a much
delayed second nuclear peak of NFĸB. Therefore, a reduction in
the effective TNFα dose due to interference of DCF with TNFα
binding to its receptor apparently would not be sufﬁcient to
explain the experimentally observed more transient IKK activation
and the shift in the second peak of nuclear NFκB. To corroborate
these model-based insights, we analyzed by single-molecule
localization microscopy (SMLM) whether DCF affects the number
of TNFR1 complexes present on the plasma membrane of HepG2
cells (Fig. 4b–e). HepG2 cells were stimulated with TNFα for 2, 5,
and 10min or were left unstimulated. The TNFR1 cluster density at
the cell membrane of unstimulated HepG2 cells showed a broad
distribution with a mean value of 1.1 ± 0.1 clusters per μm² (Fig.
4d, Table S10), which is comparable to previous results obtained
for HeLa cells.27 The stimulation of HepG2 cells with TNFα did not
signiﬁcantly change the density of TNFR1 clusters at the cell
membrane at the indicated time points. Similarly, co-treatment
with DCF did not induce a change in the number of TNFR1 clusters
(Fig. 4e, Table S10). Additionally, we investigated the size of TNFR1
clusters by analyzing SMLM data using the cluster algorithm
DBSCAN.28 We found a homogeneous distribution of TNFR1
cluster size in unstimulated cells with a mean radius of 28.7 ±
0.4 nm. The cluster radius was not altered upon stimulation with
TNFα and co-treatment with DCF (see Table S10) indicating that
DCF neither changes the number nor the size of TNFR1 clusters in
the plasma membrane of HepG2 cells. Together with the model-
based insights these results suggest that DCF does not impact the
TNFR1, but rather targets intracellular reactions of the NFκB
signaling pathway and thereby shifts the positioning and height
of the second peak of nuclear NFκB.
Mathematical model-based exploration of mechanism explaining
the impact of DCF on TNFα-induced NFκB signal transduction
To identify mechanisms explaining the impact of DCF on
intracellular TNFα-induced NFκB signal transduction, we again
utilized our TNFα signaling DCF model to theoretically examine
the dynamic behavior of the concentration of unobserved species
in response to TNFα stimulation compared to the co-treatment
with TNFα and DCF.
The comparison of nuclear NFĸB and IĸBα proﬁles in response
to both treatments indicated that nuclear accumulation of IĸBα
and low levels of NFĸB in the nucleus are highly correlated (Fig.
5a). One explanation could be that the lack of nuclear NFĸB
prevents complex formation between NFĸB and IĸBα and as a
consequence IĸBα accumulates in the nucleus. To test this
hypothesis, we examined the reaction ﬂuxes controlling the
amount of NFĸB in the nucleus: nuclear NFĸB import (positive ﬂux)
and complex formation between NFĸB and IĸBα leading to export
of NFĸB to the cytoplasm (negative ﬂux) (Fig. 5b). If the lack of
nuclear NFĸB prevented complex formation, the ﬂuxes would drop
to zero at some time points due to the absence of NFκB. However,
according to the prediction of the model, the inﬂux of NFκB into
the nucleus and the efﬂux upon complex formation are different
from zero, even if the amount of NFκB is very small. This indicated
that any NFĸB molecule transported into the nucleus will, at the
same rate, leave the nucleus in a complex with IĸBα. Since the
maximal NFĸB ﬂux is limited, the accumulation of nuclear IĸBα can
be traced back to the level of IĸBα in the cytoplasm. If the level
rises above a certain threshold, the NFĸB ﬂux is insufﬁcient to
counteract the increased IĸBα import and IĸBα will accumulate in
the nucleus.
Because the phosphorylation of IĸBα by pIKK as well as the
production and degradation of IĸBα mRNA were among the DCF-
targeted reaction rates, we investigated IκBα levels in the
cytoplasm (Fig. 5c). Because the transport ﬂux of IκBα into the
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nucleus is proportional to the levels of IκBα in the cytoplasm, the
threshold of when the IκBα inﬂux balances out the NFκB inﬂux can
be computed (dashed lines in Fig. 5c). The shaded areas in Fig. 5c
mark the time frames where cytoplasmic IĸBα levels exceed the
computed threshold and more IĸBα than NFĸB is transported to
the nucleus, and IĸBα is expected to accumulate in the nucleus.
On the one hand, the comparison between TNFα and DCF co-
treated and DCF-untreated cells showed that the IĸBα production
and degradation are reduced by DCF co-treatment leading to a
slower but prolonged IĸBα aggregation in DCF co-treated cells.
Accordingly, IĸBα exceeded the threshold slightly later and
intersected it again 110min after TNFα and DCF co-stimulation,
corresponding to the position of the maximum concentration of
nuclear IĸBα (Fig. 5a). On the other hand, the inﬂux of NFĸB to the
nucleus depends on its release from the NFĸB:IĸBα complex, and
consequently depends directly on the pIKK levels. We hypothe-
sized that lower levels of IKK activation would reduce the IĸBα
threshold concentration of when the IĸBα inﬂux into the nucleus
exceeds the NFĸB inﬂux. An extended phase of low concentrations
of nuclear NFκB would be the consequence. Therefore, to further
examine consequences of the DCF impact on IKK, we predicted
the experimentally unobserved concentrations of active pIKK and
inactive ppIKK by our dynamic pathway model. The estimated
parameters suggested that DCF accelerates the transition from
active pIKK to inactive ppIKK (Fig. 5d). Accordingly, the IĸBα
threshold shown in Fig. 5c was lowered in TNFα and DCF co-
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Fig. 5 Model prediction of DCF-induced changes in the NFκB pathway. a Model-predicted time course of nuclear IκBα and of NFκB in
response to TNFα (black line) and upon TNFα and DCF co-treatment (red line). b Model simulation of the time course of the inﬂux to the state
of nuclear NFκB (brown) and efﬂux due to complex formation (yellow) in response to TNFα stimulation or upon co-treatment of TNFα and DCF.
c Model-predicted time course of cytoplasmic IκBα response to TNFα (black solid line) and upon TNFα and DCF co-treatment (red solid line).
Depending on the cytoplasmic IκBα concentration, nuclear NFκB inﬂux is lower or higher than IκBα inﬂux. The threshold concentration at
which IκBα inﬂux exceeds the NFκB inﬂux is shown as dashed black line for TNFα and as dashed red line for TNFα and DCF. Shaded areas
indicate phases of higher IκBα inﬂux leading to IκBα accumulation in the nucleus. d Model-predicted time course of active IKK (pIKK) and of
inactive IKK (ppIKK) for time points up to t= 50min. The dynamics of pIKK and ppIKK in the presence of TNFα alone (black) and the presence
of TNFα and DCF (red) are displayed. The higher pIKK level for DCF treatment at late time points is reﬂected in the crossing of IκBα thresholds
at t= 60min
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treated cells, at least during the ﬁrst hour. At later time points,
pIKK in TNFα and DCF co-treated cells was predicted to be above
the levels of pIKK in TNFα-treated cells. The model predicted that
co-treatment with DCF reduces the peak height of pIKK by around
40% (Fig. 5d), whereas the relative change of experimentally
measured IKK phosphorylation was much smaller. The discrepancy
can be explained by our four-state IKK model with two IKK states
phosphorylated at the activation site, active pIKK, and inactive
ppIKK, which cannot be distinguished by the antibody-based
measurement. Therefore, we propose that DCF decreases pIKK
and increases ppIKK, resulting in only a small change in the sum of
pIKK and ppIKK.
These results indicate that the experimentally observed shift of
the position of the second peak of nuclear NFκB in response to co-
treatment with DCF is the integrated result of two regulatory
mechanisms: the reduced IκBα production and degradation rates
prolong the presence of elevated levels of IκBα in the cytoplasm
and reduced pIKK levels lower the threshold of when cytoplasmic
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Fig. 6 Application of the dynamic pathway model to additional DILI compound data. a Impact of four selected compounds, amiodarone
(AMD, 35 µM), paracetamol (APAP, 10mM), ximelagatran (XIM, 800 µM), and ﬁaluridine (FIAU, 500 µM), on cytoplasmic IκBα, pIκBα, pIKK, and
pNFĸB levels were measured by quantitative immunoblotting in HepG2 cells treated with either TNFα alone (10 ng/ml) or TNFα (10 ng/ml) and
the respective compound (n= 3–4, raw data in Figs. S30–S45). Data points with 1σ conﬁdence intervals are shown as dots and error bars in
different colors for different compounds, black indicating the TNFα treatment alone. The model ﬁt for the reduced compound-impact model
is shown as solid line. Model calibration involves only experiment-speciﬁc observation parameters and the two compound-speciﬁc effect
parameters α and β. b The model-predicted dynamics of nuclear NFκB for a time period of 4 h based on the short-term measurements per
compound are shown as solid lines. Data points with 1σ conﬁdence intervals for TNFα-treated cells and cells co-treated with TNFα and DCF are
shown as dots with error bars
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IκBα levels exceed the value necessary to compensate the NFĸB
inﬂux into the nucleus.
Model-based analysis of the impact of additional DILI compounds
on TNFα-induced NFκB signal transduction
After identifying IKK phosphorylation and IĸBα production/
degradation as major regulatory mechanisms affected by DCF,
additional compounds known to cause DILI including amiodarone
(AMD), paracetamol (APAP), ﬁaluridine (FIAU), and ximelagatran
(XIM) were tested. These compounds, which were previously
reported2 to represent different mechanisms of DILI, were
examined regarding their impact on TNFα-induced NFκB signal
transduction. To select most suitable DILI compound concentra-
tions, we examined, as shown in Fig. S7, the impact of increasing
concentrations of AMD, APAP, and XIM on the phosphorylation of
IκB 5min after co-stimulation with TNFα. Increasing AMD
concentrations resulted in rapid reduction of IκB phosphorylation
that was not further increased by high compound concentrations.
In line with a recent publication that reported enhanced AMD
toxicity upon co-treatment with of 35 μM AMD and TNFα, we
employed a concentration of 35 μM AMD in our experiments. For
APAP no impact on TNFα-induced IκB phosphorylation was
observed at reasonable APAP concentrations and therefore a
concentration of 10 mM APAP was selected in line with a multi-
center ring trial.29 Since XIM had no effect on TNFα-induced IκB
phosphorylation, we decided based on literature information to
apply a concentration of 800 μM XIM in our experiments. Finally,
for FIAU we observed in test experiments elevated IKKβ,
phosphorylation at 20 min of TNFα treatment. Whereas we
observed no major impact of FIAU treatment at 20 min on IκB
phosphorylation, IKKβ phosphorylation was increased. We chose a
concentration of 500 μM FIAU, which caused approximately a
doubled IKKβ phosphorylation signal intensity compared to the
control. For each of these compounds, total IĸBα, phosphorylated
IĸBα, phosphorylated IKK, and phosphorylated NFĸB in the
cytoplasm were measured by quantitative immunoblotting (Fig.
6a, data points). For co-treatment experiments with the selected
compounds and TNFα, HepG2 cells were incubated with the
compounds for 30 min prior to stimulation with TNFα and then
lysed at the indicated time points during an observation time of
up to 50min. To facilitate the analysis of the obtained time course
data by our TNFα signaling DCF model, the key mechanisms
identiﬁed for the impact of DCF were further condensed to
describe the possible impact of compounds by only two
parameters α and β. The parameter α is associated with IKK
phosphorylation. The phosphorylation rates of IKK and pIKK are
expressed as kIKK!pIKK = α
1  kIKK!pIKK and kpIKK!ppIKK =
α  kpIKK!ppIKK, respectively. Accordingly, larger values of α shift
the IKK phosphorylation from pIKK to ppIKK. The parameter β is
associated with the production and degradation rates of IĸBα. The
corresponding rates are modiﬁed on the mRNA level, k0!mIκBα =
β1  k0!mIκBα and kmIκBα!0 = β1  kmIκBα!0. Accordingly, larger
values of β slow down IĸBα mRNA production and degradation for
ﬁxed equilibrium constant. The parameters α and β are
compound-speciﬁc, i.e., they are determined for each compound
separately.
First, this simpliﬁed model was employed to estimate α and β
from the original data obtained for TNFα and DCF co-stimulation.
Only the time points and targets that were also measured for the
selected compounds were used. Based on these estimates, the
dynamics of nuclear NFĸB was predicted (Fig. 6b). The results
revealed that the simpliﬁed model is capable to correctly predict,
based on cytoplasmic measurements restricted to the ﬁrst 50 min
of stimulation, the position of the second peak of nuclear NFκB at
180min. The information necessary for this prediction is encoded
in the slight time shift of IKK phosphorylation and the decelerated
IĸBα dynamics.
Assuming that AMD, XIM, APAP, and FIAU might affect the
regulatory mechanisms in a similar way, we used the time course
data obtained for these compounds to estimate the compound-
speciﬁc values for α and β. The analysis revealed that the
mathematical model is capable to describe the time course data
for AMD, XIM, and APAP, but not for FIAU (Fig. 6a). Experimental
data and model trajectories showed that AMD shifted the TNFα-
induced IKK phosphorylation similar to DCF, whereas the effect on
IĸBα was barely noticeable. The reduced IKK phosphorylation
resulted in an extended time frame of low concentrations of
nuclear NFĸB (Fig. 6b). In contrast, APAP showed a strong effect on
IĸBα but almost no effect on IKK phosphorylation. Consequently,
the second NFĸB peak was delayed but the time frame of low
nuclear NFĸB concentration was not as extended as for AMD.
Finally, XIM neither showed effects on IĸBα nor on IKK
phosphorylation. Accordingly, the predicted nuclear NFĸB proﬁle
resembled the TNFα-stimulated control data. Because both AMD
and APAP seemed to exhibit only one of the identiﬁed drug-
induced effects, the delay of the TNFα-induced NFĸB peak was not
as strong as for DCF. The measurements taken from TNFα and
FIAU co-treated cells showed effects on the basal IKK and NFĸB
phosphorylation that were not observed for any of the other
compounds. These data indicated that an additional mechanism is
involved in the case of FIAU that is not covered by our
mathematical model.
For DCF the simpliﬁed mechanism of action allowed to estimate
drug-speciﬁc parameters that enable the prediction of the
dynamics of nuclear NFκB. Within the analysis of likely interactions
of DCF with the NFκB pathway, we found that DCF apparently
directly modiﬁes the production of A20 (direct impact), whereas
the delayed dynamics of nuclear NFκB (mediated impact) alone is
not sufﬁcient to correctly describe the observed A20 dynamics. An
evaluation of the possible impact of the other DILI compounds on
the cytoplasmic concentration of A20 is presented in Fig. S6, and
compares by model simulations a possible direct and an indirect
mechanism. The obtained results indicated that AMD is likely to
affect the A20 dynamics in a similar way as DCF. APAP and XIM
have a smaller inhibitory effect on the A20 concentration in the
cytoplasm and FIAU could even increase the production of A20.
In summary, our model-based approach enables us to quantify
the impact of DILI compounds on TNFα-induced NFκB signal
transduction using IKK phosphorylation and IĸBα production/
degradation as major characteristics of DILI compounds within the
TNFα-induced NFκB signaling pathway.
DISCUSSION
DILI accounts for most of the cases of drug non-approval,
withdrawal and abandonment of drugs.30,31 In current clinical
trials, drug hepatotoxicity still is a major problem because patient-
speciﬁc effects are unclear and DILI may occur after long latency
periods. The heterogeneity of responses suggests that some event
during the course of therapy renders the patients particularly
sensitive and this could be inﬂammatory episodes. The histolo-
gical evaluation of liver biopsies revealed elevated inﬂammatory
scores in samples from DILI patients32 and serum proteomic
proﬁling of patients with DILI showed an increase of components
associated with inﬂammation.33 In numerous animal studies
evidence was provided that even a mild inﬂammation can
decrease the threshold for hepatotoxicity and thereby enhance
the sensitivity to chemically induced damage in the liver.34–36
Interestingly, it was suggested that the major pro-inﬂammatory
cytokine TNFα is capable of enhancing liver damage in rodents
caused by different xenobiotics.37–39 An interaction between
inﬂammation and DCF in inducing hepatotoxicity was observed in
rats,40 suggesting that inﬂammatory stress is a susceptibility factor
for DCF-mediated toxicity. Furthermore, AMD treatment of rats
during inﬂammation led to liver injury and increased TNFα serum
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concentrations contributing to hepatotoxicity.41 For APAP it was
observed that TNFα is released in response to APAP intoxication
and it was proposed that TNFα is responsible for certain
pathological manifestations of APAP-induced hepatotoxicity.42
Whereas for these DILI compounds some information is available
regarding a potential impact of inﬂammatory responses on
hepatoxicity, for XIM-induced hepatotoxicity an immune-related
mechanism was suggested, and FIAU shows a human-speciﬁc
mitochondrial toxicity,2 and hence the impact of inﬂammation is
less clear. Our model-based approach provides the means to
systematically evaluate the impact of DILI compounds on TNFα-
induced responses and resolve similarities as well as distinctions.
Current approaches are limited in the ability to cover the
variability of patients and there is an urgent need for improved
test systems. Mathematical modeling offers a powerful approach
to tackle these challenges, because several factors affecting the
outcome of drug exposure to hepatocytes can be investigated, the
effects can be quantiﬁed and unobserved states can be predicted.
Thereby, regulatory mechanisms affected by DILI compounds can
be elucidated to improve possibilities to predict DILI.
One of the top ten DILI-causing drugs is DCF. It was shown that
TNFα enhances the cytotoxicity of DCF4 and that DCF interferes
with TNFα-induced NFκB signal transduction4 and causes several
stress responses.5,43 TNFα is a pleiotropic cytokine that promotes
proliferative but also cytotoxic responses,7,9,44–47 and therefore
interference with the tightly regulated balance of responses due
to drug exposure could shift the threshold toward hepatotoxicity.
However, the underlying mechanisms of how compounds such as
DCF affect TNFα-induced NFκB signal transduction in particular
during early time points was previously not resolved. We
developed a dynamic pathway model of TNFα-induced NFκB
signal transduction that enabled us to quantitatively examine the
perturbations caused by compounds and to analyze the processes
at the beginning of a cellular decision, which appear to be crucial
for cell survival under drug exposure.
Compared to previous mathematical models of NFκB signal
transduction,11–14,17,48 we extended the dynamic pathway model
of TNFα-induced NFκB signal transduction by several aspects. First,
we introduced all four states of IKK upon TNFα stimulation into our
mathematical model. In the study conducted by Behar and
colleagues, the authors suggested a particularly important role of
IKK in modulating NFκB signal transduction. This proposition is
supported by our mathematical model, which identiﬁed reduced
IKK activation as a major effect of DCF. Further, our analysis
suggested that DCF enhanced the inactivation of phosphorylated
IKK (pIKK) due to phosphorylation at the C terminus (ppIKK). Both
effects lead to reduced levels of pIKK, and consequently delayed
NFκB signal transduction. Second, we applied four states of the
NFκB:IκBα complex. Based on NFκB and IκBα phosphorylation data
in combination with Co-IP experiments, we were able to
distinguish these four states.
The resulting identiﬁable mathematical model was capable of
describing the experimental data generated for HepG2 cells and
for PHHs and identiﬁed by employing L1 regularization two major
interaction points of DCF in the NFκB signal transduction pathway.
We showed that both regulatory levels, the upstream kinase IKK
and the free, cytoplasmic IκBα, deﬁne the hepatotoxic outcome of
compound treatments. To conﬁrm the broad applicability of the
established dynamic pathway model, we translated the regulatory
mechanisms found for DCF to test scenarios with four other DILI-
causing drugs with diverse putative mechanisms.2 Although their
different mechanisms might lead to diverse rate modiﬁcations
within the NFκB pathway, it is likely that the key regulators
identiﬁed for DCF would be affected by the other DILI compounds
as well. Model calibration based on the TNFα-induced dynamics of
the NFκB pathway upon co-treatment with amiodarone, para-
cetamol, ximelagatran, and ﬁaluridine allowed us to quantify the
drug-induced effect strengths relative to DCF and predict the
dynamics of nuclear translocation of NFκB upon co-treatment with
these compounds.
Amiodarone is an antiarrhythmic lipophilic compound that was
described to accumulate in the liver,49 a scenario that is often
excluded in pharmacokinetic studies.50 It was observed that
amiodarone induces severe hepatotoxicity in rats and TNFα
contributes to a decrease of the drug toxicity threshold.41
Furthermore, TNFα co-treatment in Hepa1c1c7 cells revealed that
TNFα potentiated the amiodarone-induced cytotoxicity.51 Con-
cordant with these studies, our studies showed an early effect of
amiodarone on TNFα-induced NFκB signal transduction and
therefore highlight the importance of the integration of inﬂam-
matory responses in amiodarone-induced liver injury. Interest-
ingly, co-treatment of amiodarone with TNFα caused similar death
(caspases) and stress responses as co-treatment with DCF,4,5,51
which is reﬂected by our observed similar effects of DCF and
amiodarone on the TNFα-induced dynamics of pIKK, pIκBα, and
pNFκB (Fig. 6). However, the rather small differences on the
dynamics of IκBα indicated potential differences in the modes of
subsequent cell death, as seen in comparison to paracetamol,
which does not induce the activation of caspases but rather
necroptosis.52,53 In contrast to DCF and amiodarone, paracetamol
is affecting neither the phosphorylation of IKK nor IκBα, but is
decreasing the levels of IκBα and the phosphorylation of NFκB
(Fig. 6). The impact of paracetamol could thereby be described by
our dynamic pathway model. These observations point to a
slightly different mechanism that includes the activation of other
pathways, e.g., the JNK by paracetamol.54–56 Even though the
hepatotoxicity caused by paracetamol is rather complex and other
mechanisms might also play a role,2 we could detect and integrate
the effects caused by paracetamol with our dynamic pathway
model.
As seen in the case of ﬁaluridine our model still has limitations.
It is proposed that this compound has mitotoxic effects57;
however, previous in vitro assays failed to detect ﬁaluridine as
hepatotoxic compound and underlying mechanisms apparently
are very complex. Only recently, a 3D PHH spheroid model system
was described which facilitated the detection of ﬁaluridine toxicity
in vitro,58 thus providing a starting point for further studies, which
can be combined with our approach and used to further improve
the established dynamic pathway model.
Ximelagatran showed no effects on TNFα-induced NFκB signal
transduction in our studies, which is in line with previous reports
suggesting an immune-mediated mechanism. Extensive studies
were performed to unravel mechanisms contributing to the
hepatotoxicity of ximelagatran; however, no underlying mechan-
ism could be deﬁned. The metabolism of ximelagatran does not
involve the CYP450 system and reactive metabolites are not
formed.2 Neither did hepatotoxicity by ximelagatran show a dose
dependency.59 Due to a distinct geographic distribution of liver
injury after ximelagatran treatment, the involvement of genetic
factors was suggested.59 Recently, it was reported based on in
silico and in vitro studies that ximelagatran directly interacts with a
human leukocyte antigen strengthening the hypothesis of an
immune response mechanism.60
DCF is known to generate protein adducts in hepatocytes.61 In
addition, previous studies showed that DCF interferes with TNFα-
induced NFκB signal transduction.4,5 Because membrane recep-
tors are the starting point of various signal transduction pathways,
we quantiﬁed the impact of TNFα and of the co-treatment with
DCF on the number of TNFR1 receptor clusters per μm² and their
size at the plasma membrane. A previous study indicated that
subtle changes in TNFα–TNFR1 interactions might lead to higher-
order clustering.62 We showed by SMLM that co-treatment with
TNFα and DCF did neither signiﬁcantly change the number of
TNFR1 clusters per μm² both for stimulated or for non-stimulated
cells nor did it change the cluster size. In line with these results our
model-based studies revealed that reduced activation of the
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TNFR1 due to interference of DCF is not sufﬁcient to explain the
impact we detected on the dynamics of TNFα-induced NFκB signal
transduction.
Taken together, the developed mathematical model provides a
unique tool to quantitatively assess already in the preclinical
phase the impact of compounds on a major aspect of
inﬂammatory signaling such as TNFα-induced NFκB signal
transduction. Our approach enables us to predict the interaction
points of several compounds within the TNFα-induced NFκB
signaling pathway even though the tested compounds have
different putative toxicity mechanisms.2 Apparently, even if the
induced death pathways differ between the tested compounds,
for example, mainly via apoptosis for DCF4,63,64 or via necroptosis
as for paracetamol,52,53 already rather early effects on TNFα-
induced NFκB signal transduction are detectable. Based on these
quantitative data, our dynamic pathway model is capable to
quantify the compound-induced impact on nuclear NFκB and
thereby predict how these compounds interfere with NFκB-
induced transcription.
METHODS
Reagents and antibodies
Recombinant human TNFα (210-TA) was acquired from R&D Systems and
was reconstituted in sterile PBS containing 0.3% BSA. Diclofenac sodium
(DCF, D6899), amiodarone hydrochloride (AMD, A8423), paracetamol
(APAP, A7085), and ﬁaluridine (FIAU, SML0632) were obtained from Sigma.
Ximelagatran (XIM) was obtained from AstraZeneca. All compounds were
dissolved in DMSO (Sigma). The antibodies against pIKKα/β (#2697), IKKβ
(#2370), IKKα (#2682), pNFκB (#3031), NFκB (#6956), pIκBα (#2859), and
IκBα (#9242) were from purchased from Cell Signaling Technologies.
Secondary horseradish peroxidase-coupled antibodies were obtained from
Dianova.
Cell lines, cell culture, and cell stimulation
Human hepatoma HepG2 cells (HB8065) were obtained from American
Type Culture Collection, cultured in Dulbecco’s Modiﬁed Eagle Medium
(DMEM) without phenol red (Gibco 31053-044) supplemented with 10% (v/
v) fetal bovine serum, 1% (v/v) Penicillin/Streptomycin (Gibco), 2 mM L-
Glutamine (Gibco), and 1mM Sodium Pyruvate (Gibco) and used for
experiments between passage 5 and 20. The HepG2 cell line was
authenticated using Multiplex Cell Authentication and the purity of cell
line was validated using the Multiplex Cell Contamination Test by
Multiplexion (Heidelberg, Germany) as described recently.65,66 HepG2 cells
were serum-starved over night with DMEM supplemented with 1mg/ml
BSA, 1% (v/v) Penicillin/Streptomycin (Gibco), and 2mM L-Glutamine
(Gibco). DCF was dissolved in DMSO as 200-fold stock and prepared freshly
for every experiment. Cells were incubated for 30min with DCF (ﬁnal
concentration 500 μM) or the respective compound (ﬁnal concentration
AMD 35 μM; APAP 10mM; XIM 800 μM; FIAU 500mM) before treatment
with TNFα (ﬁnal concentration 10 ng/ml).
Primary human hepatocytes
Fresh PHHs were isolated as previously described29 from three different
donors (104, 105 and, 107 from UoL) with the following characteristics:
ID General information
Sex Age Weight
(kg)
BMI Ethnicity BP Alcohol
units/
week
Cigarettes/
day
104 M 85 80.7 30 Caucasian 178/
75
Ex smoker
20 years
105 F 45 70.9 25.4 Caucasian 132/
87
10 Ex smoker
107 M 60 81.6 26.3 Caucasian 104/
64
Ex smoker
ID Patient health
Diagnosis Disease
104 ×3 CRLM (right hepatectomy ×1
VIII, ×2 VI)
Anterior resection (BowelCa
T4bN2M0), AF, hypertension,
DMT2, osteoarthritis
105 Bismuth 3A+ caudate lobe
cholangioCA (radical bile duct
excision+ en bloc right
hemihepatectomy+ caudate
lobectomy+ partial IVC
resection)
Hysterectomy
107 ×3 CRLM (VI resected, III
metastasectomy, IV ablated)
Defun ileosotomy, AP resection
(rectalCa T4N2M0 R1), relapse
lung+ liver, lung ablation, liver
ablation, lung+ liver ablation
ID Medication excluding chemotherapy
Drug Dose Frequency
104 NKDA, metformin, bisoprolol,
perindopril
500mg/
1.25mg/
4mg
Three daily/
once daily/once
daily
105 Morphine sensitivity, omeprazole,
vitamin B12, paracetamol, piriton,
HRT
107 NKDA, loperamide PRN
ID Chemotherapy
Drug
104 5FU
105 None
107 Chemoradio cetuximab, irinotecan/FOLFOX/FOLFOX
Liver resections were received as surgical waste from Aintree Hospital,
Liverpool, UK, with full patient consent and ethical approval from the
National Research Ethics Service (REC reference: 11/NW/0327). After
isolation, cells were seeded onto collagen I coated 6-well plates and after
an adhesion time of 3 h medium and cells were left for overnight
incubation. Cells were then washed three times the next day and medium
was replaced by growth factor depletion medium (Williams Medium E
(Biochrome), 2 mM L-Glutamine (Gibco), and 1% (v/v) Penicillin/Strepto-
mycin (Gibco)) for 4 h prior to the experiment.
Time-resolved experiments and cell lysis
For time course experiments, HepG2 cells or PHHs were stimulated with
recombinant human TNFα after DCF pre-treatment of 30min for the
indicated times. Cells were then lysed using a cell lysis buffer (150mM
NaCl; 20mM Tris-HCl pH 7.4; 10 mM NaF; 1 mM EDTA pH 8; 1 mM ZnCl2 pH
4.0; 1 mM MgCl2; 1 mM Na3VO4; 10% glycerol; 1% (v/v) NP-40; 0.1%
Aprotinin; 0.1% 4-(2-Aminoethyl) benzenesulfonyl-ﬂuoride hydrochloride)
and lysates were rotated for 20min at 4 °C, the total protein concentration
of the supernatant was measured (bicinchoninic acid assay, Pierce) and
aliquots of 30 μg were made for quantitative immunoblotting.
Immunoprecipitation
For immunoprecipitation with IκBα antibody (Cell Signaling #9242) and
NFκB antibody (Cell Signaling #6956), 500 μg of the protein lysate was
used. Protein A-Sepharose (GE Healthcare) and indicated antibodies were
added to the cell lysates and immunoprecipitation was performed
overnight at 4 °C.
SDS-PAGE, quantitative immunoblotting, and data processing
Total cell lysate aliquots or immunoprecipitations were loaded in a
randomized order on 10% SDS-polyacrylamide gel electrophoresis gel
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(SDS-PAGE), separated by electrophoresis and transferred onto a
polyvinylidene diﬂuoride membrane (Millipore). Primary antibodies were
incubated overnight at 4 °C and secondary antibodies for 1 h at room
temperature. Chemiluminescence detection was performed using
enhanced chemiluminescence substrate (GE Healthcare) and charge-
coupled device camera-based signal detection was performed using an
ImageQuant LAS 4000 system (GE Healthcare). Quantiﬁcation was
performed using ImageQuant TL (GE Healthcare). Appropriate lanes were
manually selected and the width of all lanes was ﬁxed. Protein bands of
interest were manually selected and the height of the quantiﬁcation
square was adjusted to optimize the coverage of the selected protein band
and reduce the amount of background included. Compensations for band
distortions were added as necessary. The background was subtracted with
the rolling ball method.
Live-cell imaging
HepG2 RelA-GFP (NF-kB, p65) and A20-GFP BAC reporter cell lines were
generated and characterized as described previously.67 Accumulation of
GFP levels or nuclear translocation, and Hoechst staining was monitored
using a Nikon TiE2000 confocal laser microscope (lasers: 640, 540, 488, and
408 nm). This microscope is equipped with an automated stage and
perfect focus system at 37 °C with humidiﬁed atmosphere and 5% CO2/air
mixture. During starvation overnight, HepG2 cells were stained with 50 ng/
ml Hoechst33342 to visualize the nuclei. The Hoechst medium was replaced
with exposure medium containing DCF. After 30min pre-exposure to
compound only, the medium was spiked with TNFα (1:20 dilution in
starvation medium) up to a ﬁnal concentration of 10 ng/ml TNFα. To
prevent a delay in TNFα response in the oscillations of the RelA-GFP
reporter, TNFα was added at the microscope per well, directly upon
imaging of the ﬁrst image (t= 0). Quantitative image analysis was
performed with CellProﬁler version 2.1.168 with an in house developed
module implementing the watershed masked algorithm for improved
nuclear segmentation.69 Image analysis results were stored as HDF5 ﬁles,
png images with the segmentation results were stored for quality control.
Data analysis and further quality control was performed using the in house
developed R package H5CellProﬁler. Quantitative data of three indepen-
dent experiments were used for model input.
Single-molecule localization microscopy and data analysis
For single-molecule microscopy experiments, cells were seeded into 8-well
chamber slides (Sarstedt) and grown until conﬂuency was achieved. FCS-
free medium containing 0.1% BSA was applied at least 12 h prior to
experiments to the cells for starvation. For DCF treatment, cells were either
treated with 500 μM DCF in DMSO (ﬁnal concentration of DMSO: 0.5% (v/
v)) or with DMSO (0.5% (v/v) in culture media) as control. For TNFα
(ImmunoTools) treatment, cells were either treated with 10 ng/ml in PBS
supplemented with 0.3% BSA (ﬁnal concentration of BSA 3 × 10−4% (w/v))
or with BSA only as a control condition (ﬁnal concentration of BSA 3 ×
10−4%). After incubation with DCF for 30min, TNFα was added to the
medium and co-incubated for 0, 2, 5, or 10min. After incubation, cells were
ﬁxed and prepared for immunostaining.
For ﬁxation, medium was removed and cells were washed with pre-
warmed 400mM sucrose (37 °C) (Merck). Cells were incubated in ﬁxation
buffer (4% formaldehyde (methanol free; Thermo Scientiﬁc), 0.1%
glutaraldehyde (Sigma), and 400mM sucrose) for 15min. Samples were
extensively washed (at least three times) in PBS, followed by blocking in 2%
BSA for 30min. Samples were incubated with a primary antibody solution
(monoclonal mouse anti-hTNFR1 (Abcam, clone: H398), 3 μg/ml in 2% BSA)
for 1 h at room temperature. Primary antibody solution was removed by at
least three washing steps in PBS. Cells were incubated in secondary
antibody solution (F(ab′)2 fragment-goat anti-mouse labeled with Alexa-
Fluor647 (A-21237, Life Technologies), 2 μg/ml in 2% BSA) for 1 h at room
temperature, followed by three washing steps in PBS. After ﬁxation with 4%
formaldehyde, cells were washed at least three times with PBS. For negative
control measurements, cells were incubated with secondary antibody only.
SMLM experiments were performed with a custom-built setup as
described earlier.70 Brieﬂy, an inverted microscope (Olympus IX71,
Olympus) equipped with a nose piece (Olympus) was used. A read out
laser emitting at 643 nm (diode laser, iBEAM smart, Toptica) was coupled
into an acousto-optic tunable ﬁlter (AAOptics) for illumination intensity
adjustment. A second laser emitting at 405 nm (CUBE 405-50C, Coherent)
was combined with the 643 nm laser with an appropriate dichroic mirror.
Wideﬁeld illumination was achieved by focusing the laser beams onto the
back-focal plane of a 100× oil immersion objective (PLAPO 100× TIRFM,
NA ≥ 1.45, Olympus). A translatable mirror was used for switching between
wideﬁeld and total internal reﬂection illumination. Fluorescence emission
was detected by the same objective, and ﬂuorescence light was ﬁltered
with a bandpass ﬁlter (ET 700/75, AHF) and imaged with an EMCCD camera
(DU-897U-CSO-#BV, iXon Ultra, Andor). The magniﬁcation optics led to an
effective image pixel size of 157 nm.
SMLM imaging was performed following the dSTORM protocol.71 An
imaging buffer (10% w/v glucose (Sigma), 40 mg/ml catalase (Sigma),
0.5 mg/ml glucose oxidase (Sigma), and 100mM β-mercaptoethylamine
(MEA; Sigma) in PBS, pH 7.8–8) was added to the sample. Laser intensities
of 2–2.5 kW/cm² (643 nm) were used for read out of the ﬂuorescence
signal. Appropriate switching rates were achieved by UV illumination
ranging between 0–10W/cm². An image series of 20,000 frames per cell
were recorded with an integration time of 30ms per frame.
Single-molecule data were analyzed with rapidSTORM.72 Super-resolved
images were generated at a pixel size of 10 nm and further analyzed using
the LAMA package73 which can be obtained free of charge (http://share.
smb.uni-frankfurt.de/).
The localization precision was calculated using a nearest neighbor
analysis.74 The number of TNFR1 clusters was determined by an image-
based analysis routine as described earlier.27 Brieﬂy, a region of interest
(ROI) was chosen for each cell and the number of TNFR1 clusters per μm²
was determined using the Fiji Plugin “Analyze Particles”.75 The size of
individual clusters was determined for ﬁve ROI per cell, each with a size of
2 × 2 μm² using Density-Based Spatial Clustering of Applications with Noise
(DBSCAN)28 with input parameters Nmin= 10 and ε= 30 nm. Subsequently,
the radius of coextensive clusters with circular shape was calculated. For
each condition, at least 13 cells were analyzed from at least 3 different
independent experiments. Statistical hypotheses were tested using
Kolmogorov–Smirnov test implemented in OriginPro 9.1G (OriginLab).
This test allows probing similarity of small, non-normal distributed
populations (signiﬁcance level α= 0.05).
Mathematical modeling
The TNF⍺/NFκB signaling pathway is modeled by ODEs. Interactions
between species are assumed to follow mass-action kinetics. The model
topology and details about the model equations are described in
Supplementary Material 1. All modeling steps, from model setup to
identiﬁability analysis, parameter estimation, and uncertainty analysis were
carried out using the R package dMod available on the Comprehensive R
Archive Network.
The dynamic model is described by ODEs _x = f(x, pdyn) where x denotes
the vector of dynamic states such as IKK, NFκB, IκB⍺, etc., and pdyn denotes
the vector of model parameters such as activation rates, dissociation rates,
etc. Initial values x0= x(t= 0) for all dynamic states are treated like model
parameters. The dynamic states are linked to experimental observations
via an observation function y= g(x, pobs). This function accounts for the
fact that (i) only certain combinations of dynamic states can be
experimentally observed, that (ii) measurements from ﬂuorescence
microscopy suffer from photobleaching and that (iii) observations are
evaluated on the log scale.
Identiﬁability analysis
The structure of the differential equations and the observation function
can induce symmetries, i.e., a functional relationship between the model,
initial value, and observation parameters that guarantee the invariance of
the predicted observation. The TNF⍺/NFκB model was systematically
scanned for such relationships using a Lie-group approach.76 The number
of free parameters necessary to describe the model was thereby reduced.
Parameterization and steady states
The same model and observation structure is employed to describe
different experimental conditions such as TNFα/no TNFα or DCF/no DCF.
However, depending on the condition, parameters are set differently:
model, initial value, and observation parameters are obtained by
condition-speciﬁc functions, (pdyn, x0, pobs)i= ϕi(θ) from one single,
overarching vector of parameters, θ. Different experimental conditions
are denoted by i. The functions ϕi used for the TNF⍺/NFκB model account
for (i) DCF/TNF-speciﬁc setting of parameters, (ii) a general log transform of
all parameters, and (iii) a steady-state transformation where all initial values
x0 are computed from the dynamic parameters pdyn and total levels of IKK
and NFκB based on the condition f(x0, pdyn)= 0.
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Data preprocessing
Experiments were performed in at least three biological replicates. Samples
for quantitative immunoblot analysis from different replicates but equal
experimental conditions were partially measured on the same gel, whereas
others were measured on different gels. Replicates measured by
ﬂuorescence microscopy were analyzed on independent plates on
different days. Accordingly, to account for a systematic deviance between
equal conditions but different gels/plates, we used the scaling model
Si;k;n ¼ yi;nsk with the measurements Si,k,n for different conditions i, gels/plates
k, and timepoints tn. The symbols yi,n indicate time course parameters and
sk denotes scaling parameters. The time course parameters were obtained
by maximum-likelihood estimation. They represent the average dynamics
over all biological replicates. As such they condense the original replicate
data and replace it for dynamic modeling.
Parameter estimation by the maximum-likelihood method
The model response, i.e., the dynamics of the pathway species and the
corresponding observation are parameterized by the parameters θ. These
parameters are estimated by the maximum-likelihood method. Our
likelihood is based on the normal distribution, i.e., differences between
the model’s prediction for the observation at timepoints tn and the actual
observations yi,n are normally distributed: (g ∘ x ∘ ϕi (tn, θ)− yi,n) ~ N(0, σ2(θ)).
Observations for different timepoints are assumed to be statistically
independent. The expected variance σ2(θ) of the residuals is constant per
observed target, but unknown, and is therefore expressed by additional
parameters collected in θ. From these assumptions, the deviance, i.e.,
minus twice the log-likelihood is derived:
l θð Þ ¼
X
i;n
g  x  ϕi tn; θð Þ  yi;n
σ θð Þ
 2
þ log σ2 θð Þ : (1)
The function l(θ) is minimized with respect to θ to obtain parameter
estimates θ^.
Uncertainty analysis and model reduction
Parameter uncertainty was analyzed by the proﬁle-likelihood method.77
The method is not only suited to determine parameter uncertainty in
nonlinear models, it is also convenient to determine relationships between
the model parameters and to propose possible model reductions.78 Based
on the proﬁle-likelihood approach (Fig. S4) and the experimental data for
TNFα-induced NFκB signaling, the initial model was reduced to a core
model (Fig. S5). Within this model, key parameters to be altered to describe
the TNFα-induced response of DCF-treated cells were identiﬁed.
L1 regularization
Identiﬁcation of DCF-speciﬁc parameter alterations is based on the LASSO
method.26 At ﬁrst, every reaction rate was considered as a possible target
of DCF. The altered rate k* of any reaction rate k is related to its original
value by the equation k*= k · rk or, equivalently, applying the logarithm,
log(k*)= log(k)+ Δk, where Δk= log(rk). Introducing the L1 regularization
function ϕλ Δkð Þ ¼ λ
P
k
Δkj j, the augmented objective function can be
expressed as:
lλ k;Δkð Þ ¼ l kjdatacontrol
 þ l k  eΔk jdataDCF
 þ ϕλ Δkð Þ: (2)
Here, l kjdatacontrol
 
and l k  eΔk jdataDCFð Þ describe twice the negative log-
likelihood of the model given the TNFα-stimulated control data and of the
model with modiﬁed rates given the data of TNFα and DCF co-treated cells,
respectively. First, the objective function lλ(k, Δk) was minimized for λ= 0. In
this setting, the difference parameters Δk could be freely estimated, allowing
changes in all parameters in response to DCF treatment. Subsequently, λ was
gradually increased. Larger values of λ increase the pressure to reduce the Δ-
values, eventually leading to zero values. In this case, no parameter
differences between the control and the DCF data is allowed.
Data availability
The reactions of the full and the reduced model are shown in Tables S1
and S5, respectively, with the corresponding differential equations in
Tables S2 and S6. The observation functions linking the states of the ODE
model to the experimentally observed quantities are listed in Table S3. The
estimated model parameters are shown in Tables S7–S9. The density of
TFNFR1 clusters and corresponding cluster radii are shown in Table S10.
Quantitative immunoblots for all the experimental data is shown in Figs.
S8–S45. Data that have been used for mathematical modeling is provided
as Data Set csv ﬁle.
Code availability
The custom R packages blotIt2 and dMod used for data preprocessing with
a scaling model and parameter estimation in ODE models, respectively, are
available on github as open source R packages under the GPL license
(https://github.com/dkaschek/blotIt2, https://github.com/dkaschek/dMod).
The ODE model as being implemented in dMod is available on https://
github.com/dkaschek/dMod_Examples. The concepts and usage of dMod
have been introduced previously.79
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